This inventor holds 1 USPTO granted patent. Top assignee: Evox Therapeutics Ltd. Active years: 2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2022
Title: Per Lundin: Innovator in Extracellular Vesicle Technology
Introduction
Per Lundin is a notable inventor based in Stockholm, Sweden. He has made significant contributions to the field of biotechnology, particularly in the area of extracellular vesicles (EVs). His innovative work focuses on enhancing the delivery of pharmacological agents using advanced methods.
Latest Patents
Per Lundin holds 1 patent related to his groundbreaking research. His patent, titled "Cell penetrating peptide (CPP)-mediated EV loading," outlines methods for loading extracellular vesicles with pharmacological agents. The invention highlights the use of cell-penetrating peptides as carriers into EVs, employing either non-covalent or covalent loading approaches. This technology has promising medical applications, including compositions that incorporate pharmacological agent-loaded EVs.
Career Highlights
Per Lundin is currently associated with Evox Therapeutics Ltd., a company dedicated to advancing EV technology for therapeutic purposes. His work at Evox Therapeutics has positioned him as a key player in the development of innovative solutions in the biotechnology sector.
Collaborations
Some of his notable coworkers include Oscar Wiklander and Dhanu Gupta, who contribute to the collaborative efforts in research and development at Evox Therapeutics.
Conclusion
Per Lundin's contributions to the field of extracellular vesicle technology exemplify the innovative spirit of modern biotechnology. His work continues to pave the way for new therapeutic strategies that could significantly impact medical treatments in the future.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile